



WHAT IS CLAIMED IS:

1. A method of treating a chemokine mediated disease state, or a disease state mediated by a receptor of the chemokine, in a mammal in need of such treatment, which comprises administering to the mammal an effective amount of a compound selected from the group consisting of compounds of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV) or (XV) or a pharmaceutically acceptable salt thereof:


(I)




(II)




(III)




(IV)



(V)




(VI)



TOTAL F= CHOLESTEROLO


10

(VII)




15


(VIII)



(IX)




(X)




TOEETTE = 0000000000000000


10 (XI)




(XII)



(XIII)




(XIV)



10

(XV)



wherein:

"a" is 0 or an integer from 1 to 8;

"b" is 0 or an integer from 1 to 7;

"c" is 0 or an integer from 1 to 6;

"d" is 0 or an integer from 1 to 10;

"e" is 0 or an integer from 1 to 10;

5 Ring A is aromatic or non-aromatic and may optionally be heterocyclic with one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;

Ring B is aromatic or non-aromatic and may optionally be heterocyclic with one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;

Ring C is aromatic or non-aromatic and may optionally be heterocyclic with one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;

10 R_1 , R_2 and R_3 at each occurrence may independently be selected from substituents having 25 or fewer atoms, wherein the substituent may be selected from the group consisting of: H; substituted or unsubstituted alkyls; substituted or unsubstituted C_{1-10} alkyls; substituted or unsubstituted C_{1-6} alkyls; substituted or unsubstituted cycloalkyls; substituted or unsubstituted C_{3-6} cycloalkyls; substituted or unsubstituted alkenyls; substituted or unsubstituted C_{2-6} alkenyls; substituted or unsubstituted alkynyls; substituted or unsubstituted C_{2-6} alkynyls; substituted or unsubstituted aryls; substituted or unsubstituted heterocycles; hydroxyls; aminos; nitros; thiols; primary, secondary or tertiary amines; imines; amides; phosphonates; phosphines; carbonyls; carboxyls; silyls; ethers; thioethers; sulfonyls; sulfonates; selenoethers; ketones; aldehydes; esters; $-CF_3$; $-CN$; and combinations thereof;

20 R_4 , R_5 and R_6 at each occurrence may independently be selected from substituents having 20 or fewer atoms, wherein the substituent may be selected from the group consisting of: H; substituted or unsubstituted alkyls; substituted or unsubstituted C_{1-10} alkyls; substituted or unsubstituted C_{1-6} alkyls; substituted or unsubstituted cycloalkyls; substituted or unsubstituted C_{3-6} cycloalkyls; substituted or unsubstituted alkenyls; substituted or unsubstituted C_{2-6} alkenyls; substituted or unsubstituted alkynyls; substituted or unsubstituted C_{2-6} alkynyls; substituted or unsubstituted aryls; substituted or unsubstituted heterocycles; hydroxyls; aminos; nitros; thiols; primary, secondary or tertiary amines; imines; amides; phosphonates; phosphines; carbonyls; carboxyls; silyls; ethers; thioethers; sulfonyls; sulfonates; selenoethers; ketones; aldehydes; esters; $-CF_3$; $-CN$; and combinations thereof;

25 R_1 , R_2 , R_3 R_4 , R_5 and R_6 may together define one or more exocyclic rings joining one or more of Rings A, B and C, and an exocyclic ring may be heterocyclic;

30

"chiral" denotes that a compound may be chiral; and,


the chemokine receptor is selected from the group consisting of CCR-1, CCR-3, CCR-4 and CCR-5 and the chemokine is selected from the group consisting of RANTES and chemokines that bind to the chemokine receptor.

5


2. A method of modulating the activity of a chemokine or a chemokine receptor in host, comprising administering to the host an effective amount of a compound selected from the group consisting of compounds of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV) or (XV) or a pharmaceutically acceptable salt thereof:

10

(I)




(II)




15


(III)




(IV)



(V)




(VI)




THE EASY WAY TO LEARN CHEMISTRY


10 (VII)




(VIII)




(IX)




(X)




10 (XI)




(XII)



(XIII)




(XIV)



10

(XV)




wherein:

"a" is 0 or an integer from 1 to 8;
"b" is 0 or an integer from 1 to 7;
"c" is 0 or an integer from 1 to 6;
"d" is 0 or an integer from 1 to 10;
5 "e" is 0 or an integer from 1 to 10;
Ring A is aromatic or non-aromatic and may optionally be heterocyclic with one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;
Ring B is aromatic or non-aromatic and may optionally be heterocyclic with one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;
10 Ring C is aromatic or non-aromatic and may optionally be heterocyclic with one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;
R₁, R₂ and R₃ at each occurrence are independently selected from substituents having 25 or fewer atoms, wherein the substituent may be selected from the group consisting of: H; substituted or unsubstituted alkyls; substituted or unsubstituted C₁₋₁₀ alkyls; substituted or unsubstituted C₁₋₆ alkyls; substituted or unsubstituted cycloalkyls; substituted or unsubstituted C₃₋₆ cycloalkyls; substituted or unsubstituted alkenyls; substituted or unsubstituted C₂₋₆ alkenyls; substituted or unsubstituted alkynyls; substituted or unsubstituted C₂₋₆ alkynyls; substituted or unsubstituted aryls; substituted or unsubstituted heterocycles; hydroxyls; aminos; nitros; thiols; primary, secondary or tertiary amines; imines; amides; phosphonates; phosphines; carbonyls; carboxyls; silyls; ethers; thioethers; 20 sulfonyls; sulfonates; selenoethers; ketones; aldehydes; esters; -CF₃; -CN; and combinations thereof;
R₄, R₅ and R₆ at each occurrence are independently selected from substituents having 20 or fewer atoms, wherein the substituent may be selected from the group consisting of: H; substituted or unsubstituted alkyls; substituted or unsubstituted C₁₋₁₀ alkyls; substituted or unsubstituted C₁₋₆ alkyls; substituted or unsubstituted cycloalkyls; substituted or unsubstituted C₃₋₆ cycloalkyls; substituted or unsubstituted alkenyls; substituted or unsubstituted C₂₋₆ alkenyls; substituted or unsubstituted alkynyls; substituted or unsubstituted C₂₋₆ alkynyls; substituted or unsubstituted aryls; substituted or unsubstituted heterocycles; hydroxyls; aminos; nitros; thiols; primary, secondary or tertiary amines; imines; amides; phosphonates; phosphines; carbonyls; carboxyls; silyls; ethers; thioethers; 25 sulfonyls; sulfonates; selenoethers; ketones; aldehydes; esters; -CF₃; -CN; and combinations thereof;
sulfonyls; sulfonates; selenoethers; ketones; aldehydes; esters; -CF₃; -CN; and combinations thereof;
30


R₁, R₂, R₃ R₄, R₅ and R₆ may together define one or more exocyclic rings joining one or more of Rings A, B and C, and an exocyclic ring may be heterocyclic;
"chiral" denotes that a compound may be chiral; and,
the chemokine receptor is selected from the group consisting of CCR-1, CCR-3, CCR-4 and CCR-5
5 and the chemokine is selected from the group consisting of RANTES and chemokines that bind to the chemokine receptor.

3. A method of inhibiting the interaction of a chemokine with a chemokine receptor in a mammal, comprising administering to the mammal an effective amount of a compound selected
10 from the group consisting of compounds of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV) or (XV) or a pharmaceutically acceptable salt thereof:


(I)




(II)




(III)




(IV)



(V)




(VI)




ESTER CONGENERS

10


(VII)




(VIII)




(IX)




(X)




10 (XI)




(XII)



(XIII)




(XIV)



10

(XV)



wherein:

"a" is 0 or an integer from 1 to 8;
"b" is 0 or an integer from 1 to 7;
"c" is 0 or an integer from 1 to 6;
"d" is 0 or an integer from 1 to 10;
5 "e" is 0 or an integer from 1 to 10;

Ring A is aromatic or non-aromatic and may optionally be heterocyclic with one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;

Ring B is aromatic or non-aromatic and may optionally be heterocyclic with one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;

10 Ring C is aromatic or non-aromatic and may optionally be heterocyclic with one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;

R₁, R₂ and R₃ at each occurrence may independently be selected from substituents having 25 or fewer atoms, wherein the substituent may be selected from the group consisting of: H; substituted or unsubstituted alkyls; substituted or unsubstituted C₁₋₁₀ alkyls; substituted or unsubstituted C₁₋₆ alkyls; substituted or unsubstituted cycloalkyls; substituted or unsubstituted C₃₋₆ cycloalkyls; substituted or unsubstituted alkenyls; substituted or unsubstituted C₂₋₆ alkenyls; substituted or unsubstituted alkynyls; substituted or unsubstituted C₂₋₆ alkynyls; substituted or unsubstituted aryls; substituted or unsubstituted heterocycles; hydroxyls; aminos; nitros; thiols; primary, secondary or tertiary amines; imines; amides; phosphonates; phosphines; carbonyls; carboxyls; silyls; ethers; thioethers; sulfonyls; sulfonates; selenoethers; ketones; aldehydes; esters; -CF₃; -CN; and combinations thereof;

R₄, R₅ and R₆ at each occurrence may independently be selected from substituents having 20 or fewer atoms, wherein the substituent may be selected from the group consisting of: H; substituted or unsubstituted alkyls; substituted or unsubstituted C₁₋₁₀ alkyls; substituted or unsubstituted C₁₋₆ alkyls; substituted or unsubstituted cycloalkyls; substituted or unsubstituted C₃₋₆ cycloalkyls; substituted or unsubstituted alkenyls; substituted or unsubstituted C₂₋₆ alkenyls; substituted or unsubstituted alkynyls; substituted or unsubstituted C₂₋₆ alkynyls; substituted or unsubstituted aryls; substituted or unsubstituted heterocycles; hydroxyls; aminos; nitros; thiols; primary, secondary or tertiary amines; imines; amides; phosphonates; phosphines; carbonyls; carboxyls; silyls; ethers; thioethers; sulfonyls; sulfonates; selenoethers; ketones; aldehydes; esters; -CF₃; -CN; and combinations thereof;

25 substituted or unsubstituted cycloalkyls; substituted or unsubstituted C₃₋₆ cycloalkyls; substituted or unsubstituted alkenyls; substituted or unsubstituted C₂₋₆ alkenyls; substituted or unsubstituted alkynyls; substituted or unsubstituted C₂₋₆ alkynyls; substituted or unsubstituted aryls; substituted or unsubstituted heterocycles; hydroxyls; aminos; nitros; thiols; primary, secondary or tertiary amines; imines; amides; phosphonates; phosphines; carbonyls; carboxyls; silyls; ethers; thioethers; sulfonyls; sulfonates; selenoethers; ketones; aldehydes; esters; -CF₃; -CN; and combinations thereof;

30 substituted or unsubstituted cycloalkyls; substituted or unsubstituted C₃₋₆ cycloalkyls; substituted or unsubstituted alkenyls; substituted or unsubstituted C₂₋₆ alkenyls; substituted or unsubstituted alkynyls; substituted or unsubstituted C₂₋₆ alkynyls; substituted or unsubstituted aryls; substituted or unsubstituted heterocycles; hydroxyls; aminos; nitros; thiols; primary, secondary or tertiary amines; imines; amides; phosphonates; phosphines; carbonyls; carboxyls; silyls; ethers; thioethers; sulfonyls; sulfonates; selenoethers; ketones; aldehydes; esters; -CF₃; -CN; and combinations thereof;

R₁, R₂, R₃ R₄, R₅ and R₆ may together define one or more exocyclic rings joining one or more of Rings A, B and C, and an exocyclic ring may be heterocyclic;

"chiral" denotes that a compound may be chiral; and,

the chemokine receptor is selected from the group consisting of CCR-1, CCR-3, CCR-4 and CCR-5 and the chemokine is selected from the group consisting of RANTES and chemokines that bind to the chemokine receptor.

4. The method of claim 1, wherein the compound binds to the chemokine receptor with a binding affinity below 100 nM.

5. The method of claim 2, wherein the compound binds to the chemokine receptor with a binding affinity below 100 nM.


6. The method of claim 3, wherein the compound binds to the chemokine receptor with a binding affinity below 100 nM.

7. The method of claim 1, wherein the chemokine mediated disease is selected from the group consisting of autoimmune diseases, inflammation, chronic and acute inflammation, psoriasis, gout, acute pseudogout, acute gouty arthritis, arthritis, rheumatoid arthritis, osteoarthritis, allograft rejection, chronic transplant rejection, asthma, atherosclerosis, cardiovascular, mononuclear-phagocyte dependent lung injury, idiopathic pulmonary fibrosis, atopic dermatitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute chest syndrome in sickle cell disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, septic shock, endotoxic shock, urosepsis, glomerulonephritis, lupus nephritis, thrombosis, graft vs. host reaction, angiogenesis, NSCLC, ovarian cancer, pancreatic cancer, breast carcinoma, colon carcinoma, rectum carcinoma, lung carcinoma, oropharynx carcinoma, hypopharynx carcinoma, esophagus carcinoma, stomach carcinoma, pancreas carcinoma, liver carcinoma, gallbladder carcinoma, bile duct carcinoma, small intestine carcinoma, urinary tract carcinoma, kidney carcinoma, bladder carcinoma, urothelium carcinoma, female genital tract carcinoma, cervix carcinoma, uterus carcinoma, ovarian carcinoma, choriocarcinoma, gestational trophoblastic disease, male genital tract carcinoma, prostate carcinoma, seminal vesicles carcinoma, testes carcinoma, germ cell tumors, endocrine gland carcinoma, thyroid carcinoma, adrenal carcinoma, pituitary gland carcinoma, skin


carcinoma, hemangiomas, melanomas, sarcomas, bone and soft tissue sarcoma, Kaposi's sarcoma, tumors of the brain, tumors of the nerves, tumors of the eyes, tumors of the meninges, astrocytomas, gliomas, glioblastomas, retinoblastomas, neuromas, neuroblastomas, Schwannomas, meningiomas, solid tumors arising from hematopoietic malignancies (such as leukemias, chloromas, 5 plasmacytomas and the plaques and tumors of mycosis fungoides and cutaneous T-cell lymphoma/leukemia), solid tumors arising from lymphomas, viral infections and HIV infection.

8. A pharmaceutical composition comprising a compound selected from the group consisting of compounds of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), 10 (XIV) or (XV), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient or diluent:


(I)




(II)




(III)




(IV)




(V)




(VI)




10 (VII)




(VIII)



(IX)




(X)




STRUCTURE OF A STEROID


10 (XI)




(XII)



(XIII)




(XIV)



10

(XV)



wherein:

"a" is 0 or an integer from 1 to 8;

PCT/US2015/046650

"b" is 0 or an integer from 1 to 7;

"c" is 0 or an integer from 1 to 6;

"d" is 0 or an integer from 1 to 10;

"e" is 0 or an integer from 1 to 10;

5 Ring A is aromatic or non-aromatic and may optionally be heterocyclic with one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;

Ring B is aromatic or non-aromatic and may optionally be heterocyclic with one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;

Ring C is aromatic or non-aromatic and may optionally be heterocyclic with one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;

10 R₁, R₂ and R₃ at each occurrence may independently be selected from substituents having 25 or fewer atoms, wherein the substituent may be selected from the group consisting of: H; substituted or unsubstituted alkyls; substituted or unsubstituted C₁₋₁₀ alkyls; substituted or unsubstituted C₁₋₆ alkyls; substituted or unsubstituted cycloalkyls; substituted or unsubstituted C₃₋₆ cycloalkyls; substituted or unsubstituted alkenyls; substituted or unsubstituted C₂₋₆ alkenyls; substituted or unsubstituted alkynyls; substituted or unsubstituted C₂₋₆ alkynyls; substituted or unsubstituted aryls; substituted or unsubstituted heterocycles; hydroxyls; aminos; nitros; thiols; primary, secondary or tertiary amines; imines; amides; phosphonates; phosphines; carbonyls; carboxyls; silyls; ethers; thioethers; sulfonyls; sulfonates; selenoethers; ketones; aldehydes; esters; -CF₃; -CN; and combinations thereof;

15 R₄, R₅ and R₆ at each occurrence may independently be selected from substituents having 20 or fewer atoms, wherein the substituent may be selected from the group consisting of: H; substituted or unsubstituted alkyls; substituted or unsubstituted C₁₋₁₀ alkyls; substituted or unsubstituted C₁₋₆ alkyls; substituted or unsubstituted cycloalkyls; substituted or unsubstituted C₃₋₆ cycloalkyls; substituted or 20 unsubstituted alkenyls; substituted or unsubstituted C₂₋₆ alkenyls; substituted or unsubstituted alkynyls; substituted or unsubstituted C₂₋₆ alkynyls; substituted or unsubstituted aryls; substituted or unsubstituted heterocycles; hydroxyls; aminos; nitros; thiols; primary, secondary or tertiary amines; imines; amides; phosphonates; phosphines; carbonyls; carboxyls; silyls; ethers; thioethers; sulfonyls; sulfonates; selenoethers; ketones; aldehydes; esters; -CF₃; -CN; and combinations thereof;

25 R₁, R₂, R₃ R₄, R₅ and R₆ may together define one or more exocyclic rings joining one or more of Rings A, B and C, and an exocyclic ring may be heterocyclic;


30

"chiral" denotes that a compound may be chiral; and,

the compound binds with high affinity to a chemokine receptor selected from the group consisting of CCR-1, CCR-3, CCR-4 and CCR-5.


5 9. The pharmaceutical composition of claim 8, wherein the compound has the following
formula:

(II)




10. The pharmaceutical composition of claim 8, wherein the compound has the following formula:

(III)




15 11. The pharmaceutical composition of claim 8, wherein the compound has the following formula:

(IV)



12. The pharmaceutical composition of claim 8, wherein the compound has the following formula:


(V)



5

13. The pharmaceutical composition of claim 8, wherein the compound has the following formula:


(VI)



10
11
12
13
14
15
16
17
18
19
20

14. The pharmaceutical composition of claim 8, wherein the compound has the following formula:


(VII)



15


15. The pharmaceutical composition of claim 8, wherein the compound has the following formula:

(VIII)




16. The pharmaceutical composition of claim 8, wherein the compound has the following
5 formula:

(IX)




17. The pharmaceutical composition of claim 8, wherein the compound has the following
10 formula:

(X)



18. The pharmaceutical composition of claim 8, wherein the compound has the following formula:


(XI)



5

19. The pharmaceutical composition of claim 8, wherein the compound has the following formula:


(XII)



Patent Application
101300

20. The pharmaceutical composition of claim 8, wherein the compound has the following formula:


(XIII)



15

21. The pharmaceutical composition of claim 8, wherein the compound has the following formula:


(XIV)



5

22. The pharmaceutical composition of claim 8, wherein the compound has the following formula:


(XV)



10
11
12
13
14
15


23. The method of claim 1, wherein the compound has the following formula:

(II)




15 24. The method of claim 1, wherein the compound has the following formula:

(III)




25. The method of claim 1, wherein the compound has the following formula:

5 (IV)



26. The method of claim 1, wherein the compound has the following formula:


(V)



10

27. The method of claim 1, wherein the compound has the following formula:


(VI)



15


28. The method of claim 1, wherein the compound has the following formula:

(VII)




5 29. The method of claim 1, wherein the compound has the following formula:

(VIII)



30. The method of claim 1, wherein the compound has the following formula:

(IX)




31. The method of claim 1, wherein the compound has the following formula:

100-105-106-107-108-109-110
111-112-113-114-115-116-117-118-119-120
121-122-123-124-125-126-127-128-129-130
131-132-133-134-135-136-137-138-139-140
141-142-143-144-145-146-147-148-149-150
151-152-153-154-155-156-157-158-159-160
161-162-163-164-165-166-167-168-169-170
171-172-173-174-175-176-177-178-179-180
181-182-183-184-185-186-187-188-189-190
191-192-193-194-195-196-197-198-199-199
200-201-202-203-204-205-206-207-208-209
210-211-212-213-214-215-216-217-218-219
220-221-222-223-224-225-226-227-228-229
230-231-232-233-234-235-236-237-238-239
240-241-242-243-244-245-246-247-248-249
250-251-252-253-254-255-256-257-258-259
260-261-262-263-264-265-266-267-268-269
270-271-272-273-274-275-276-277-278-279
280-281-282-283-284-285-286-287-288-289
290-291-292-293-294-295-296-297-298-299
299-300-301-302-303-304-305-306-307-308
309-310-311-312-313-314-315-316-317-318
319-320-321-322-323-324-325-326-327-328
329-330-331-332-333-334-335-336-337-338
339-340-341-342-343-344-345-346-347-348
349-350-351-352-353-354-355-356-357-358
359-360-361-362-363-364-365-366-367-368
369-370-371-372-373-374-375-376-377-378
379-380-381-382-383-384-385-386-387-388
389-390-391-392-393-394-395-396-397-398
399-400-401-402-403-404-405-406-407-408
409-410-411-412-413-414-415-416-417-418
419-420-421-422-423-424-425-426-427-428
429-430-431-432-433-434-435-436-437-438
439-440-441-442-443-444-445-446-447-448
449-450-451-452-453-454-455-456-457-458
459-460-461-462-463-464-465-466-467-468
469-470-471-472-473-474-475-476-477-478
479-480-481-482-483-484-485-486-487-488
489-490-491-492-493-494-495-496-497-498
499-500-501-502-503-504-505-506-507-508
509-510-511-512-513-514-515-516-517-518
519-520-521-522-523-524-525-526-527-528
529-530-531-532-533-534-535-536-537-538
539-540-541-542-543-544-545-546-547-548
549-550-551-552-553-554-555-556-557-558
559-560-561-562-563-564-565-566-567-568
569-570-571-572-573-574-575-576-577-578
579-580-581-582-583-584-585-586-587-588
589-590-591-592-593-594-595-596-597-598
599-600-601-602-603-604-605-606-607-608
609-610-611-612-613-614-615-616-617-618
619-620-621-622-623-624-625-626-627-628
629-630-631-632-633-634-635-636-637-638
639-640-641-642-643-644-645-646-647-648
649-650-651-652-653-654-655-656-657-658
659-660-661-662-663-664-665-666-667-668
669-670-671-672-673-674-675-676-677-678
679-680-681-682-683-684-685-686-687-688
689-690-691-692-693-694-695-696-697-698
699-700-701-702-703-704-705-706-707-708
709-710-711-712-713-714-715-716-717-718
719-720-721-722-723-724-725-726-727-728
729-730-731-732-733-734-735-736-737-738
739-740-741-742-743-744-745-746-747-748
749-750-751-752-753-754-755-756-757-758
759-760-761-762-763-764-765-766-767-768
769-770-771-772-773-774-775-776-777-778
779-780-781-782-783-784-785-786-787-788
789-790-791-792-793-794-795-796-797-798
799-800-801-802-803-804-805-806-807-808
809-810-811-812-813-814-815-816-817-818
819-820-821-822-823-824-825-826-827-828
829-830-831-832-833-834-835-836-837-838
839-840-841-842-843-844-845-846-847-848
849-850-851-852-853-854-855-856-857-858
859-860-861-862-863-864-865-866-867-868
869-870-871-872-873-874-875-876-877-878
879-880-881-882-883-884-885-886-887-888
889-890-891-892-893-894-895-896-897-898
899-900-901-902-903-904-905-906-907-908
909-910-911-912-913-914-915-916-917-918
919-920-921-922-923-924-925-926-927-928
929-930-931-932-933-934-935-936-937-938
939-940-941-942-943-944-945-946-947-948
949-950-951-952-953-954-955-956-957-958
959-960-961-962-963-964-965-966-967-968
969-970-971-972-973-974-975-976-977-978
979-980-981-982-983-984-985-986-987-988
989-990-991-992-993-994-995-996-997-998
999-1000-1001-1002-1003-1004-1005-1006-1007-1008
1009-1010-1011-1012-1013-1014-1015-1016-1017-1018
1019-1020-1021-1022-1023-1024-1025-1026-1027-1028
1029-1030-1031-1032-1033-1034-1035-1036-1037-1038
1039-1040-1041-1042-1043-1044-1045-1046-1047-1048
1049-1050-1051-1052-1053-1054-1055-1056-1057-1058
1059-1060-1061-1062-1063-1064-1065-1066-1067-1068
1069-1070-1071-1072-1073-1074-1075-1076-1077-1078
1079-1080-1081-1082-1083-1084-1085-1086-1087-1088
1089-1090-1091-1092-1093-1094-1095-1096-1097-1098
1099-1100-1101-1102-1103-1104-1105-1106-1107-1108
1109-1110-1111-1112-1113-1114-1115-1116-1117-1118
1119-1120-1121-1122-1123-1124-1125-1126-1127-1128
1129-1130-1131-1132-1133-1134-1135-1136-1137-1138
1139-1140-1141-1142-1143-1144-1145-1146-1147-1148
1149-1150-1151-1152-1153-1154-1155-1156-1157-1158
1159-1160-1161-1162-1163-1164-1165-1166-1167-1168
1169-1170-1171-1172-1173-1174-1175-1176-1177-1178
1179-1180-1181-1182-1183-1184-1185-1186-1187-1188
1189-1190-1191-1192-1193-1194-1195-1196-1197-1198
1199-1200-1201-1202-1203-1204-1205-1206-1207-1208
1209-1210-1211-1212-1213-1214-1215-1216-1217-1218
1219-1220-1221-1222-1223-1224-1225-1226-1227-1228
1229-1230-1231-1232-1233-1234-1235-1236-1237-1238
1239-1240-1241-1242-1243-1244-1245-1246-1247-1248
1249-1250-1251-1252-1253-1254-1255-1256-1257-1258
1259-1260-1261-1262-1263-1264-1265-1266-1267-1268
1269-1270-1271-1272-1273-1274-1275-1276-1277-1278
1279-1280-1281-1282-1283-1284-1285-1286-1287-1288
1289-1290-1291-1292-1293-1294-1295-1296-1297-1298
1299-1300-1301-1302-1303-1304-1305-1306-1307-1308
1309-1310-1311-1312-1313-1314-1315-1316-1317-1318
1319-1320-1321-1322-1323-1324-1325-1326-1327-1328
1329-1330-1331-1332-1333-1334-1335-1336-1337-1338
1339-1340-1341-1342-1343-1344-1345-1346-1347-1348
1349-1350-1351-1352-1353-1354-1355-1356-1357-1358
1359-1360-1361-1362-1363-1364-1365-1366-1367-1368
1369-1370-1371-1372-1373-1374-1375-1376-1377-1378
1379-1380-1381-1382-1383-1384-1385-1386-1387-1388
1389-1390-1391-1392-1393-1394-1395-1396-1397-1398
1399-1400-1401-1402-1403-1404-1405-1406-1407-1408
1409-1410-1411-1412-1413-1414-1415-1416-1417-1418
1419-1420-1421-1422-1423-1424-1425-1426-1427-1428
1429-1430-1431-1432-1433-1434-1435-1436-1437-1438
1439-1440-1441-1442-1443-1444-1445-1446-1447-1448
1449-1450-1451-1452-1453-1454-1455-1456-1457-1458
1459-1460-1461-1462-1463-1464-1465-1466-1467-1468
1469-1470-1471-1472-1473-1474-1475-1476-1477-1478
1479-1480-1481-1482-1483-1484-1485-1486-1487-1488
1489-1490-1491-1492-1493-1494-1495-1496-1497-1498
1499-1500-1501-1502-1503-1504-1505-1506-1507-1508
1509-1510-1511-1512-1513-1514-1515-1516-1517-1518
1519-1520-1521-1522-1523-1524-1525-1526-1527-1528
1529-1530-1531-1532-1533-1534-1535-1536-1537-1538
1539-1540-1541-1542-1543-1544-1545-1546-1547-1548
1549-1550-1551-1552-1553-1554-1555-1556-1557-1558
1559-1560-1561-1562-1563-1564-1565-1566-1567-1568
1569-1570-1571-1572-1573-1574-1575-1576-1577-1578
1579-1580-1581-1582-1583-1584-1585-1586-1587-1588
1589-1590-1591-1592-1593-1594-1595-1596-1597-1598
1599-1600-1601-1602-1603-1604-1605-1606-1607-1608
1609-1610-1611-1612-1613-1614-1615-1616-1617-1618
1619-1620-1621-1622-1623-1624-1625-1626-1627-1628
1629-1630-1631-1632-1633-1634-1635-1636-1637-1638
1639-1640-1641-1642-1643-1644-1645-1646-1647-1648
1649-1650-1651-1652-1653-1654-1655-1656-1657-1658
1659-1660-1661-1662-1663-1664-1665-1666-1667-1668
1669-1670-1671-1672-1673-1674-1675-1676-1677-1678
1679-1680-1681-1682-1683-1684-1685-1686-1687-1688
1689-1690-1691-1692-1693-1694-1695-1696-1697-1698
1699-1700-1701-1702-1703-1704-1705-1706-1707-1708
1709-1710-1711-1712-1713-1714-1715-1716-1717-1718
1719-1720-1721-1722-1723-1724-1725-1726-1727-1728
1729-1730-1731-1732-1733-1734-1735-1736-1737-1738
1739-1740-1741-1742-1743-1744-1745-1746-1747-1748
1749-1750-1751-1752-1753-1754-1755-1756-1757-1758
1759-1760-1761-1762-1763-1764-1765-1766-1767-1768
1769-1770-1771-1772-1773-1774-1775-1776-1777-1778
1779-1780-1781-1782-1783-1784-1785-1786-1787-1788
1789-1790-1791-1792-1793-1794-1795-1796-1797-1798
1799-1800-1801-1802-1803-1804-1805-1806-1807-1808
1809-1810-1811-1812-1813-1814-1815-1816-1817-1818
1819-1820-1821-1822-1823-1824-1825-1826-1827-1828
1829-1830-1831-1832-1833-1834-1835-1836-1837-1838
1839-1840-1841-1842-1843-1844-1845-1846-1847-1848
1849-1850-1851-1852-1853-1854-1855-1856-1857-1858
1859-1860-1861-1862-1863-1864-1865-1866-1867-1868
1869-1870-1871-1872-1873-1874-1875-1876-1877-1878
1879-1880-1881-1882-1883-1884-1885-1886-1887-1888
1889-1890-1891-1892-1893-1894-1895-1896-1897-1898
1899-1900-1901-1902-1903-1904-1905-1906-1907-1908
1909-1910-1911-1912-1913-1914-1915-1916-1917-1918
1919-1920-1921-1922-1923-1924-1925-1926-1927-1928
1929-1930-1931-1932-1933-1934-1935-1936-1937-1938
1939-1940-1941-1942-1943-1944-1945-1946-1947-1948
1949-1950-1951-1952-1953-1954-1955-1956-1957-1958
1959-1960-1961-1962-1963-1964-1965-1966-1967-1968
1969-1970-1971-1972-1973-1974-1975-1976-1977-1978
1979-1980-1981-1982-1983-1984-1985-1986-1987-1988
1989-1990-1991-1992-1993-1994-1995-1996-1997-1998
1999-2000-2001-2002-2003-2004-2005-2006-2007-2008
2009-2010-2011-2012-2013-2014-2015-2016-2017-2018
2019-2020-2021-2022-2023-2024-2025-2026-2027-2028
2029-2030-2031-2032-2033-2034-2035-2036-2037-2038
2039-2040-2041-2042-2043-2044-2045-2046-2047-2048
2049-2050-2051-2052-2053-2054-2055-2056-2057-2058
2059-2060-2061-2062-2063-2064-2065-2066-2067-2068
2069-2070-2071-2072-2073-2074-2075-2076-2077-2078
2079-2080-2081-2082-2083-2084-2085-2086-2087-2088
2089-2090-2091-2092-2093-2094-2095-2096-2097-2098
2099-2100-2091-2092-2093-2094-2095-2096-2097-2098
2099-2100-2101-2102-2103-2104-2105-2106-2107-2108
2109-2110-2111-2112-2113-2114-2115-2116-2117-2118
2119-2120-2121-2122-2123-2124-2125-2126-2127-2128
2129-2130-2131-2132-2133-2134-2135-2136-2137-2138
2139-2140-2141-2142-2143-2144-2145-2146-2147-2148
2149-2150-2151-2152-2153-2154-2155-2156-2157-2158
2159-2160-2161-2162-2163-2164-2165-2166-2167-2168
2169-2170-2171-2172-2173-2174-2175-2176-2177-2178
2179-2180-2181-2182-2183-2184-2185-2186-2187-2188
2189-2190-2191-2192-2193-2194-2195-2196-2197-2198
2199-2200-2201-2202-2203-2204-2205-2206-2207-2208
2209-2210-2211-2212-2213-2214-2215-2216-2217-2218
2219-2220-2221-2222-2223-2224-2225-2226-2227-2228
2229-2230-2231-2232-2233-2234-2235-2236-2237-2238
2239-2240-2241-2242-2243-2244-2245-2246-2247-2248
2249-2250-2251-2252-2253-2254-2255-2256-2257-2258
2259-2260-2261-2262-2263-2264-2265-2266-2267-2268
2269-2270-2271-2272-2273-2274-2275-2276-2277-2278
2279-2280-2281-2282-2283-2284-2285-2286-2287-2288
2289-2290-2291-2292-2293-2294-2295-2296-2297-2298
2299-2300-2301-2302-2303-2304-2305-2306-2307-2308
2309-2310-2311-2312-2313-2314-2315-2316-2317-2318
2319-2320-2321-2322-2323-2324-2325-2326-2327-2328
2329-2330-2331-2332-2333-2334-2335-2336-2337-2338
2339-2340-2341-2342-2343-2344-2345-2346-2347-2348
2349-2350-2351-2352-2353-2354-2355-2356-2357-2358
2359-2360-2361-2362-2363-2364-2365-2366-2367-2368
2369-2370-2371-2372-2373-2374-2375-2376-2377-2378
2379-2380-2381-2382-2383-2384-2385-2386-2387-2388
2389-2390-2391-2392-2393-2394-2395-2396-2397-2398
2399-2400-2401-2402-2403-2404-2405-2406-2407-2408
2409-2410-2411-2412-2413-2414-2415-2416-2417-2418
2419-2420-2421-2422-2423-2424-2425-2426-2427-2428
2429-2430-2431-2432-2433-2434-2435-2436-2437-2438
2439-2440-2441-2442-2443-2444-2445-2446-2447-2448
2449-2450-2451-2452-2453-2454-2455-2456-2457-2458
2459-2460-2461-2462-2463-2464-2465-2466-2467-2468
2469-2470-2471-2472-2473-2474-2475-2476-2477-2478
2479-2480-2481-2482-2483-2484-2485-2486-2487-2488
2489-2490-2491-2492-2493-2494-2495-2496-

35. The method of claim 1, wherein the compound has the following formula:


(XIV)



5

36. The method of claim 1, wherein the compound has the following formula:

(XV)



10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100

37. The method of claim 1 wherein the disease is an autoimmune disease or an inflammatory disease in a human patient.

38. A method of treating a disease comprising administering to a patient in need of such treatment an effective amount of a RANTES receptor ligand, wherein the disease is selected from 15 the group consisting of autoimmune diseases, inflammation, chronic and acute inflammation, psoriasis, gout, acute pseudogout, acute gouty arthritis, arthritis, rheumatoid arthritis, osteoarthritis, allograft rejection, chronic transplant rejection, asthma, atherosclerosis, cardiovascular, mononuclear-phagocyte dependent lung injury, idiopathic pulmonary fibrosis, atopic dermatitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute chest syndrome in 20 sickle cell disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, septic shock, endotoxic shock, urosepsis, glomerulonephritis, lupus nephritis, thrombosis, graft vs. host reaction, angiogenesis, NSCLC, ovarian cancer, pancreatic cancer, breast carcinoma, colon carcinoma, rectum carcinoma, lung carcinoma, oropharynx carcinoma, hypopharynx carcinoma, esophagus

carcinoma, stomach carcinoma, pancreas carcinoma, liver carcinoma, gallbladder carcinoma, bile duct carcinoma, small intestine carcinoma, urinary tract carcinoma, kidney carcinoma, bladder carcinoma, urothelium carcinoma, female genital tract carcinoma, cervix carcinoma, uterus carcinoma, ovarian carcinoma, choriocarcinoma, gestational trophoblastic disease, male genital tract carcinoma, prostate carcinoma, seminal vesicles carcinoma, testes carcinoma, germ cell tumors, endocrine gland carcinoma, thyroid carcinoma, adrenal carcinoma, pituitary gland carcinoma, skin carcinoma, hemangiomas, melanomas, sarcomas, bone and soft tissue sarcoma, Kaposi's sarcoma, tumors of the brain, tumors of the nerves, tumors of the eyes, tumors of the meninges, astrocytomas, gliomas, glioblastomas, retinoblastomas, neuromas, neuroblastomas, Schwannomas, meningiomas, 10 solid tumors arising from hematopoietic malignancies (such as leukemias, chloromas, plasmacytomas and the plaques and tumors of mycosis fungoides and cutaneous T-cell lymphoma/leukemia), solid tumors arising from lymphomas, viral infections and HIV infection.